SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

“Breakthrough Therapy designation recognizes the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial as soon as possible to ...

A drug which could become the first ever treatment for Autism Spectrum Disorder has been granted Breakthrough Therapy Designation by the FDA. Roche’s investigational oral medicine balovaptan ...

An innovative treatment for debilitating and often deadly cases of recurrent C diff infection has been given a Breakthrough Therapy Designation by the FDA. Developed by US biotech firm Rebiotix ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

A groundbreaking development in diabetes treatment reveals that SGLT-2 inhibitors significantly reduce dementia risk among type 2 diabetes patients. Recent research demonstrates these medications ...